Yüklüyor......
Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody bevacizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer patients have been evaluated in clinical trials. Apart from targeting extracellular receptors by the antibody aflibercept or the p...
Kaydedildi:
| Yayımlandı: | Front Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4593253/ https://ncbi.nlm.nih.gov/pubmed/26500886 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2015.00211 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|